ALDEYRA THERAPEUTICS INC (ALDX) Stock Income Statement
NASDAQ:ALDX - Nasdaq - US01438T1060 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 61.15M | 60.12M | 42.79M | 62.68M | 56.22M | |||
| Research and Development | 49.46M | 48.22M | 29.46M | 47.31M | 44.94M | |||
| Selling, General, and Administrative Expenses | 11.69M | 11.89M | 13.34M | 15.37M | 11.28M | |||
| Operating Income | -61.15M | -60.12M | -42.79M | -62.68M | -56.22M | |||
| Interest Income/Expense | 3.45M | 4.27M | 5.25M | 660.00K | -1.56M | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | 0.00 | |||
| Income Before Taxes | -57.70M | -55.85M | -37.54M | -62.02M | -57.78M | |||
| Income Tax | N/A | N/A | N/A | N/A | 0.00 | |||
| Net Income | -57.70M | -55.85M | -37.54M | -62.02M | -57.78M | |||
| EBITDA | -60.90M | -59.87M | -42.53M | -62.42M | -55.96M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.97 | -0.94 | -0.64 | -1.06 | -1.07 | |||
| Non GAAP EPS | -0.97 | -0.94 | -0.64 | -1.06 | -1.07 | |||
| Statistics | ||||||||
All data in USD